Manufacturer of Controlled Substances; Notice of Application, 61511 [E6-17277]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 201 / Wednesday, October 18, 2006 / Notices
Alexandria, Virginia 22301; and must be
filed no later than November 17, 2006.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e) and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are and will continue to be required
to demonstrate to the Deputy Assistant
Administrator, Office of Diversion
Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a), 21 U.S.C. 823(a), and 21
CFR 1301.34(b), (c), (d), (e) and (f) are
satisfied.
Dated: October 11, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–17293 Filed 10–17–06; 8:45 am]
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Roche Diagnostics
Operations, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and § 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substances
listed.
Dated: October 11, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–17289 Filed 10–17–06; 8:45 am]
BILLING CODE 4410–09–P
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Importer of Controlled Substances;
Notice of Registration
By Notice dated June 7, 2006, and
published in the Federal Register on
June 13, 2006 (71 FR 34162), Roche
Diagnostics Operations, Inc., Attn:
Regulatory Compliance, 9115 Hague
Road, Indianapolis, Indiana 46250,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic class of controlled substances
listed in Schedule I and II:
Drug
Schedule
rmajette on PROD1PC67 with NOTICES1
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
Cocaine (9041) .............................
Ecgonine (9180) ...........................
Methadone (9250) ........................
Morphine (9300) ...........................
Alphamethadol (9605) ..................
I
I
II
II
II
II
II
The company plans to import the
listed controlled substances for the
manufacture of diagnostic products for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Roche Diagnostics Operations, Inc. to
import the basic class of controlled
substances is consistent with the public
interest and with United States
VerDate Aug<31>2005
17:47 Oct 17, 2006
Jkt 211001
Pursuant to Section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on February 27,
2006, Varian, Inc., Lake Forest, 25200
Commercentre Drive, Lake Forest,
California 92630–8810, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the basic classes of controlled
substances listed in Schedule II:
Drug
Schedule
Phencyclidine (7471) ....................
1-Piperidinocyclohexanecarbonitrile (8603).
Benzoylecgonine (9180) ...............
II
II
II
The company plans to manufacture
small quantities of the listed controlled
substances for use in diagnostic
products.
Any other such applicant and any
person who is presently registered with
DEA to manufacture such a substance
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
should be addressed, in quintuplicate,
to the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
61511
Washington, DC 20537, Attention: DEA
Federal Register Representative/ODL; or
any being sent via express mail should
be sent to DEA Headquarters, Attention:
DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than December 18, 2006.
Dated: October 11, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E6–17277 Filed 10–17–06; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Office of the Secretary
Submission for OMB Review:
Comment Request
October 13, 2006.
The Department of Labor (DOL) has
submitted the following public
information collection request (ICR) to
the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995 (Pub. L. 104–13,
44 U.S.C. Chapter 35). A copy of this
ICR, with applicable supporting
documentation, may be obtained by
contacting Ira Mills at the Department of
Labor on 202–693–4122 (this is not a
toll-free number) or E-Mail:
Mills.Ira@dol.gov. This ICR can also be
accessed online at https://
www.doleta.gov/OMBCN/
OMBControlNumber.cfm. ICRs are filed
according to the date the 60-day Notice
for Public Comment was published in
the Federal Register Notice; therefore,
on the left hand side of this site, look
under July 25, 2006 to access 1205–
0441.
Comments should be sent to Office of
Information and Regulatory Affairs,
Attn: OMB Desk Officer for ETA, Office
of Management and Budget, Room
10235, Washington, DC 20503, 202–
395–7316 (this is not a toll free number),
within 30 days from the date of this
publication in the Federal Register.
The OMB is particularly interested in
comments which:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
E:\FR\FM\18OCN1.SGM
18OCN1
]]>Agencies
[Federal Register Volume 71, Number 201 (Wednesday, October 18, 2006)]
[Notices]
[Page 61511]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-17277]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on February 27, 2006, Varian,
Inc., Lake Forest, 25200 Commercentre Drive, Lake Forest, California
92630-8810, made application by renewal to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of the
basic classes of controlled substances listed in Schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Phencyclidine (7471)....................... II
1-Piperidinocyclohexanecarbo- nitrile II
(8603).
Benzoylecgonine (9180)..................... II
------------------------------------------------------------------------
The company plans to manufacture small quantities of the listed
controlled substances for use in diagnostic products.
Any other such applicant and any person who is presently registered
with DEA to manufacture such a substance may file comments or
objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail
should be addressed, in quintuplicate, to the Deputy Assistant
Administrator, Office of Diversion Control, Drug Enforcement
Administration, Washington, DC 20537, Attention: DEA Federal Register
Representative/ODL; or any being sent via express mail should be sent
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must
be filed no later than December 18, 2006.
Dated: October 11, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-17277 Filed 10-17-06; 8:45 am]
BILLING CODE 4410-09-P
